【佳學(xué)基因檢測】發(fā)現(xiàn)差異：癌癥研究中的蛋白質(zhì)組學(xué)

基因檢測多少錢一次1萬八解剖

與專家交流發(fā)現(xiàn)《Lancet Oncol》在?2001 May;2(5):270-7發(fā)表了一篇題目為《發(fā)現(xiàn)差異：癌癥研究中的蛋白質(zhì)組學(xué)》腫瘤靶向藥物治療基因檢測臨床研究文章。該研究由L C Lawrie,?J E Fothergill,?G I Murray等完成。促進(jìn)了腫瘤的正確治療與個(gè)性化用藥的發(fā)展，進(jìn)一步強(qiáng)調(diào)了基因信息檢測與分析的重要性。

腫瘤靶向藥物及正確治療臨床研究內(nèi)容關(guān)鍵詞：

0

腫瘤靶向治療基因檢測臨床應(yīng)用結(jié)果

通過二維電泳分離數(shù)千種細(xì)胞蛋白質(zhì)，可以詳細(xì)比較來自正常組織和患病組織的蛋白質(zhì)。質(zhì)譜法提供了一種快速高效的方法來表征感興趣的蛋白質(zhì)，特別是當(dāng)源生物的基因序列已知時(shí)。人類基因組序列的可用性開辟了識別正常組織和患病組織之間蛋白質(zhì)差異的可能性，從而為尋找腫瘤標(biāo)志物或治療靶點(diǎn)提供了機(jī)會(huì)。這項(xiàng)新技術(shù)將為腫瘤發(fā)展和進(jìn)展的分子機(jī)制提供急需的洞察力。

腫瘤發(fā)生與反復(fù)轉(zhuǎn)移國際數(shù)據(jù)庫描述：

Separation of thousands of cellular proteins by two-dimensional electrophoresis allows the detailed comparison of proteins from normal and diseased tissue. Mass spectrometry provides a fast and reliable way of characterising proteins of interest, particularly when the gene sequence of the source organism is known. The availability of the human genome sequence has opened up the possibility of identifying protein differences between normal and diseased tissue, thus providing the opportunity to search for tumour markers or for therapeutic targets. This new technology will give much-needed insight into the molecular mechanisms of tumour development and progression.